title: A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study.
abstract: OBJECTIVE
  Myocardial diastolic dysfunction (MDD) and impaired coronary flow reserve (CFR) are early signs of myocardial involvement in patients with diabetes. The important question of whether this may be reversed by glucose normalization has not been tested in a controlled clinical trial. We hypothesized that strict glycaemic control, particularly if insulin based, will improve MDD and CFR.
  
  
  RESULTS
  Thirty-nine type 2 diabetes patients (mean age 61.0 +/- 7 years) with signs of diastolic dysfunction were randomly assigned to strict metabolic control by insulin (I-group; n = 21) or oral glucose lowering agents (O-group; n = 18). MDD and CFR were studied with Doppler-echocardiography including Tissue Doppler Imaging and myocardial contrast enhanced echocardiography. Fasting glucose (I-group = -2.2 +/- 2.1; O-group -1.5 +/- 0.8 mmol/L) and HbA(1c) were normalized (-0.6 +/- 0.4 and -0.7 +/- 0.4%, respectively) in both groups, but this did not significantly improve MDD in either of the groups (P = 0.65). There was no difference in CFR before and after improved glycaemic control.
  
  
  CONCLUSIONS
  The hypothesis that strict glycaemic control would reverse early signs of MDD and improve CFR in patients with type 2 diabetes could not be confirmed, despite achieved normalization. Whether it is possible to influence a more pronounced diastolic dysfunction, particularly in less well-controlled diabetic patients, remains to be established.
authors.affiliation: Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. christina.jarnert@karolinska.se
authors.forename: Christina
authors.initials: C
authors.lastname: Jarnert
authors.forename: Lena
authors.initials: L
authors.lastname: Landstedt-Hallin
authors.forename: Klas
authors.initials: K
authors.lastname: Malmberg
authors.forename: Anders
authors.initials: A
authors.lastname: Melcher
authors.forename: John
authors.initials: J
authors.lastname: Ohrvik
authors.forename: Hans
authors.initials: H
authors.lastname: Persson
authors.forename: Lars
authors.initials: L
authors.lastname: Rydén
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003326:Coronary Circulation / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000503:physiopathology; D003971:Diastole / Q000502:physiology; D015150:Echocardiography, Doppler; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000503:physiopathology*
chemical_list: D001786:Blood Glucose